BioSpace News Archive

Medal Honors Nonprofit Organizations That Embody Company’s Commitment to Expanding Access to Care for People in Need

AmeriHealth Caritas, a national leader in Medicaid managed care and other health care solutions for those most in need, announced it has signed a letter of agreement with the three individual members of the Advancing NC Whole Health Coalition

Acoustic respiration rate measurement is now, for the first time, possible for patients of all sizes, including neonates.

Interim Data Will Be Presented from Safety Study of First-of-Its-Kind Heart Failure Therapy

Polyganics today announced that it has signed an agreement with Synovis Micro Companies Alliance Inc. to be the exclusive distributor of its nerve capping device, NEUROCAP®, in the US.

Millipede, Inc., a medical device company leading the way in adding to the structural heart toolbox for the interventional cardiologist, has successfully treated two patients utilizing its latest-generation delivery system which incorporates a fully integrated intracardiac echocardiography (ICE) catheter

DaVita Kidney Care, a division of DaVita Inc. (NYSE: DVA), a leading provider of kidney care services in the United States, celebrates its more than 18,000 nephrology nurses across the U.S. and in 10 other countries around the world during Nephrology Nurses Week.

BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the appointment of Scott Smith, as President. Mr. Smith, an experienced biotechnology and pharmaceutical executive, joins the Company from Celgene Corporation, where he was President and Chief Operating Officer.

Alkermes plc (Nasdaq: ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company’s immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the FDA-approved PD-1 inhibitor KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel pharmaceutical agents based on their proprietary small molecule macrocyclic chemistry, and Haplogen Bioscience GmbH, a biotechnology company developing cutting-edge antiviral therapeutics, announced today the awarding of the internationally-recognized EUREKA label